Q2 FY2026 · ended Jun 30, 2026 · Revenue $411,000, -70.4% YoY · Filed Aug 14, 2026
Cerenome, Inc. (CNSY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $411,000 and a net loss of $9.0 million. Free cash flow was -$7.6 million. As of Jun 30, 2026 it held $8.6 million in cash and investments and $44,000 in total debt.
Revenue
$411,000
-70.4% vs year-ago quarter
Net income
$-9.01M
-274.8% vs year-ago quarter
Operating cash flow
$-7.13M
-23.0% vs year-ago quarter
Free cash flow
$-7.63M
-31.5% vs year-ago quarter
EPS
$-1.31
-718.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
7.59M
-92.4% vs year-ago quarter
Net cash
$8.54M
Q2 FY2026
Operating margin
-628.1%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CNSY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1095981
- Former names
- PLUS THERAPEUTICS, INC. (until Jul 1, 2026); CYTORI THERAPEUTICS, INC. (until Aug 2, 2019); MACROPORE INC (until Jul 5, 2005)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $411,000 | $1.0M | $1.4M | $1.4M | $1.4M |
| Operating income | -$9.1M | -$7.1M | -$5.7M | -$4.5M | -$1.5M |
| Net income | -$9.0M | -$6.9M | -$5.7M | -$4.4M | $5.2M |
| Diluted EPS | -$1.31 | -$1.05 | -$0.04 | -$0.04 | -$0.16 |
| Operating cash flow | -$7.1M | -$6.2M | -$6.3M | -$2.5M | -$5.8M |
| Free cash flow | -$7.6M | -$7.1M | -$6.3M | -$2.6M | -$5.8M |
| Total assets | $14.0M | $19.9M | $16.3M | $18.7M | $10.3M |
| Total liabilities | $8.6M | $8.0M | $12.3M | $13.6M | $7.3M |
| Stockholders' equity | $5.5M | $12.0M | $4.0M | $5.1M | $3.0M |
| Cash and investments | $8.6M | $15.1M | $8.6M | $16.6M | $6.9M |
| Total debt | $44,000 | $58,000 | $71,000 | $21,000 | $30,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 10, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 5, 2026 | Jun 1, 2026 |
All 1000 Cerenome, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.